The usefulness of blood eosinophil count as a biomarker may still need clarification following trials using GlaxoSmithKline PLC's Nucala (mepolizumab) in COPD, despite the US FDA's hopes to the contrary.
Members of the Pulmonary-Allergy Drugs Advisory Committee seemed befuddled by many of the questions FDA raised, including what eosinophil count is a reliable marker for patient benefit
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?